The primary therapeutic role of this medication is to provide foundational and long-term support for patients experiencing allergic eye diseases, focusing on preventing the onset and escalation of disruptive symptoms; it is used for several forms of allergic inflammation in the eye.

This medication is commonly used as a preemptive defense against predictable, recurrent allergic flare-ups, such as Seasonal Allergic Conjunctivitis, Perennial Allergic Conjunctivitis, and the more intense Vernal Keratoconjunctivitis. It is applied to address symptom clusters that may become intense or disruptive, including severe ocular itching, burning, eye redness, and swelling.

“Consistent use provides supportive relief when symptoms interfere with routine activities.”

The medication may assist with mitigating the overall severity and frequency of episodes by supporting management before significant exposure to environmental triggers occurs. This approach contributes to improved comfort during periods of heightened symptoms. It also plays a role in managing chronic conditions where functional stability becomes affected, offering continuous support that assists with maintaining functional stability over time.

---

Quick Fact: Relief for Acute Allergic Discomfort
This treatment domain is relevant for easing symptoms related to inflammatory or irritative states, focusing on pruritus and the associated burning sensation.

Eligibility Map: Who Can and Cannot Use Lekrolin (Sodium Cromoglicate Ophthalmic Solution) — Official Regulatory Information

This eligibility profile is based strictly on the official prescribing information and regulatory documents from government health authorities (such as the FDA and EMA).

---

Populations Excluded from Use (Contraindications)

Lekrolin is contraindicated and must not be used by individuals with a documented hypersensitivity or allergy to the active ingredient, Sodium Cromoglicate (Cromolyn Sodium), or to any of the excipients, including the preservative Benzalkonium chloride.

---

Restricted and Conditional Eligibility

Age-Related Eligibility:

• Pediatric Patients: Safety and effectiveness have not been established for children under the age of 4 years (in some regions, under 2 years). Use in these age groups is generally excluded or restricted.

Special Conditions and Physiological States:

• Soft Contact Lens Wearers: Patients must remove soft contact lenses before instillation and wait at least 15 minutes before reinserting them. This restriction is due to the presence of Benzalkonium chloride.
• Pregnancy and Lactation: Use during pregnancy is not recommended unless the potential benefit clearly outweighs the potential risk. Caution should be exercised when used by nursing mothers.
• Compromised Ocular Surface: Individuals with dry eye or a compromised cornea should use the medicine with caution.

The official regulatory profile for Лекролин (Sodium Cromoglycate Ophthalmic Solution) is characterized by a minimal risk of systemic drug interactions, which is consistently reported across government prescribing information.

Systemic Drug-Drug Interaction Profile

The active ingredient, Sodium Cromoglycate, is minimally absorbed into the systemic circulation following topical application to the eye, with only trace amounts entering the bloodstream. Furthermore, the substance is not metabolized by the liver. Consequently, official government labeling states there are no known systemic drug-drug interactions involving enzyme-mediated pathways (such as CYP450) or drug transporters that would alter the systemic exposure of other medicines or vice versa. This profile results in no formal contraindications related to co-administration with other medicinal products.

Regulatory documents explicitly state that the concomitant use of ophthalmic corticosteroids is permissible when required.

Timing and Excipient-Related Restriction

The primary documented restriction is an administration-timing rule related to the formulation’s preservative, Benzalkonium Chloride. Soft contact lenses must be removed prior to instillation of the eye drops to prevent the preservative from being absorbed by the lens material. Following application, soft contact lenses should not be reinserted for at least 15 minutes.

How Sodium Cromoglycate Works: Mast Cell Stabilization

The pharmacological action of Sodium Cromoglycate involves mast cell stabilization, intervening directly at the cellular level to prevent the initiation of the allergic response cascade. The molecule acts by stabilizing the mast cell membrane, a crucial biological process that inhibits mast cell degranulation and the subsequent release of its inflammatory contents . This stabilization is achieved primarily by inhibiting the necessary inflow of calcium ions ( Ca^2+) across the membrane, which is the molecular signal required to initiate degranulation. By locking the inflammatory contents within the mast cell, the molecule preemptively blocks the release of key mediators like Histamine and Leukotrienes. This interruption of the cascade restricts the magnitude of mediator-driven physiological signaling, meaning the mechanism preemptively interrupts the subsequent cascade of mediator-induced physiological changes, including local vasodilation and increased vascular permeability. The mechanism is entirely prophylactic; it provides no action to reverse or halt established mediator-driven physiological changes.

How to Use Лекролин

Лекролин is an ophthalmic solution containing the active ingredient Sodium Cromoglycate for topical ocular administration only. Its use is governed by a fixed, regular dosing schedule to maintain a consistent effect over time. The administration protocol emphasizes consistency and proper technique.

---

Usage Rule	Guidance
Route & Form	Administered as an eye drop solution into the conjunctival sac of the eye.
Standard Dosing	Instill 1 or 2 drops into each affected eye per dose, typically 4 to 6 times a day.
Frequency Pattern	Must be administered at regular intervals throughout the day; the frequency should not be exceeded.
Pediatric Use	Approved for use in Adults and Children 4 years of age and older; no dose adjustment is generally required for the elderly.
Duration of Course	Treatment should continue for as long as needed to sustain improvement, often throughout the period of antigen exposure. Full response may require continuous use for up to six weeks.

---

Special Administration Conditions

Proper use dictates that the applicator tip must not touch any surface, including the eye or fingers, to prevent contamination. If a dose is missed, the user is advised to apply the dose as soon as remembered, then return to the regular schedule, ensuring not to double the next dose. Users of soft contact lenses are directed to refrain from wearing the lenses while undergoing treatment, or to remove them before instillation and wait at least 15 minutes before reinsertion.

Recent Clinical Evidence: Sodium Cromoglicate

This section summarizes key findings from clinical research on sodium cromoglicate, the active ingredient in Lekrolin, focusing on its evaluation in treating allergic conjunctivitis.

---

Mechanism of Study and Efficacy Findings

Sodium cromoglicate is classified as a mast cell stabilizer. Studies have investigated its effect by evaluating its potential to prevent the release of inflammatory mediators, such as histamine, from mast cells in the conjunctiva when exposed to an allergen. This action is explored primarily in the prophylactic use of the medication.

Clinical trials have examined the effectiveness of sodium cromoglicate compared to placebo in reducing symptoms associated with seasonal and perennial allergic conjunctivitis.

Study Type	Primary Outcome Measured	Key Findings
Randomized Controlled Trials (RCTs)	Patient-reported ocular itching and tearing scores.	Statistically significant differences were observed in patient symptom scores when treatment was initiated before or early in the allergy season, compared to placebo.
Long-term Safety Studies	Incidence of local adverse effects over 6 months.	The drug was generally reported to be well-tolerated, with minimal systemic absorption.

---

Tolerability and Safety Profile

Research indicates that sodium cromoglicate is associated with a low incidence of severe adverse events. The most commonly reported side effects observed during trials are localized and include transient eye irritation, stinging, or burning immediately following administration. These effects are typically mild and short-lived.

No evidence suggests the development of tolerance over prolonged periods of use in the studies conducted.

Key Studies & References

1. Safety and Tolerability of Sodium Cromoglycate in Pediatric and Adult Populations: A Post-marketing Surveillance Study

Common questions about Лекролин (FAQ)

---

Q: How long does it take for Lekrolin to start working to relieve my symptoms?

Clinical studies indicate that an initial reduction in symptoms, such as itching and tearing, may be observed within a few days of starting treatment. However, since the medicine works preventatively by stabilizing mast cells, the full therapeutic benefit may require continuous use for up to six weeks, as stated in the official product information.

---

Q: Is it OK to use Lekrolin while pregnant or breastfeeding?

Regulatory documents indicate that use during pregnancy is advised only when the potential benefit is considered to clearly outweigh the potential risk. For breastfeeding, the systemic absorption of the active ingredient is expected to be very low. Due to this low absorption, some expert panels consider use during this period as a low-risk option, but caution should still be exercised.

---

Q: Where in my eye should I actually put the eye drop?

Official product information states that the eye drop is administered into the conjunctival sac of the affected eye. This is typically done by creating a small space between the lower eyelid and the eyeball, as detailed in the patient information leaflet accompanying the medication.

---

Q: What do I do with the unused drops after the 28-day period?

Multi-dose bottles of the ophthalmic solution must be discarded 28 days after the bottle is first opened, regardless of the amount of solution remaining. This restriction is critical for preventing possible contamination. Unused single-dose units and expired product must be disposed of following local regulatory guidelines for pharmaceutical waste.

---

Q: Does Lekrolin contain a steroid or an antihistamine?

Lekrolin is not a steroid and is not classified as an antihistamine. Its active ingredient, Sodium Cromoglycate, is a mast cell stabilizer that works by preventing the release of inflammatory chemicals like histamine. This provides a foundational, preventative approach to managing allergic eye symptoms.

How to Store and Dispose of Sodium Cromoglycate (Lecrolin/Лекролин)

Storage Conditions

Sodium Cromoglycate ophthalmic solution must be stored below a maximum temperature of 25 C or 30 C and protected from light. The container must be kept in the original outer carton and out of the sight and reach of children.

Do not refrigerate or freeze the drops, as this may compromise the solution's integrity. For multi-dose bottles, the container must be kept tightly closed after each use.

Stability and Disposal

To prevent contamination, multi-dose bottles must be discarded 28 days after first opening. Single-dose units must be used immediately and discarded right away.

Unused or expired product must not be thrown away via wastewater or household waste. Disposal must be conducted in accordance with local regulatory requirements for pharmaceutical waste.